Scott brings more than 30 years of strategic and operational leadership experience to his role as CEO of Trinity. He has spent much of his career helping life sciences companies address commercial challenges across the pharmaceutical, biotechnology, and contract research sectors.
Before becoming CEO in 2025, Scott served on Trinity’s Board of Advisors for three years, gaining a detailed view of the company’s culture, clients, and priorities and helping shape its long-term vision. His leadership centers on building collaborative, high-performing teams and guiding organizations through change while preserving what makes them distinctive.
Scott currently serves on the board of Worldwide Clinical Trials and advises on growth and innovation as an Operating Executive at Kohlberg. His previous leadership roles span IQVIA, Ironshore Pharmaceuticals, and Deloitte, and he also founded Swiftwater Group.
In his role at Trinity, Scott focuses on combining the firm’s deep expertise and technology to help clients navigate complex commercialization decisions and deliver better outcomes for patients, clients, and employees.